Paul Hastings LLP has advised Aktis Oncology on its upsized initial public offering. Aktis Oncology, a clinical?stage biotechnology company developing radiopharmaceuticals for cancer treatment, has successfully…
Aktis Oncology Prices $317.7 Million Initial Public Offering
